Liquid biopsy in CNS tumors: Current status & future perspectives

Simple item page
dc.contributor.authorHusain, Nen_US
dc.contributor.authorHusain, Aen_US
dc.contributor.authorMishra, Sen_US
dc.contributor.authorSrivastava, P.en_US
dc.date.accessioned2023-08-10T07:32:34Z
dc.date.available2023-08-10T07:32:34Z
dc.date.issued2022-05
dc.description.abstractPrecise classification of central nervous system (CNS) malignancies is vital for the treatment and prognostication. Identification of noninvasive markers can be of importance to guide treatment decisions and in monitoring treatment response. CNS tumors are classified based on morphology with an essential complement of molecular changes, including mutations, amplifications, and methylation. Neuroimaging is the mainstay for initial diagnosis and monitoring tumor response with obvious limitations of imprecise tumor typing and no information on diagnostic, predictive and prognostic markers. Liquid biopsy has evolved as a diagnostic tool in body fluids and is being investigated as a surrogate for tissue biopsy in managing primary and metastatic brain tumors. Liquid biopsy refers to analyzing biological fluids such as peripheral blood, urine, pleural effusion, ascites, and cerebrospinal fluid (CSF); however, peripheral blood remains the primary source of fluid biopsy. The analytes include cell-free DNA (cfDNA) circulating tumor cells (CTCs), circulating micro RNAs (miRNAs), circulating proteins and extracellular vesicles (EVs). Analysis of these components is actively used for early cancer detection, auxiliary staging, prognosis assessment, detection of minimal residual disease (MRD), and monitoring drug resistance in various solid tumors. In recent years, liquid biopsy has been studied in CNS tumors, and analysis of CTCs and cfDNA have become relevant research topics. In the current review, we have explained the clinical potential of liquid biopsy in CNS tumors to assist in diagnosing and predicting prognosis and response to treatment.en_US
dc.identifier.affiliationsDepartment of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, Indiaen_US
dc.identifier.citationHusain N, Husain A, Mishra S, Srivastava P.. Liquid biopsy in CNS tumors: Current status & future perspectives. Indian Journal of Pathology & Microbiology. 2022 May; 65(1): 111-121en_US
dc.identifier.issn0377-4929
dc.identifier.issn0974-5130
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223272
dc.languageenen_US
dc.publisherWolters Kluwer - Medknowen_US
dc.relation.issuenumber1en_US
dc.relation.volume65en_US
dc.source.urihttps://doi.org/10.4103/ijpm.ijpm_1058_21en_US
dc.subjectcfDNAen_US
dc.subjectcirculating miRNAen_US
dc.subjectCNS tumorsen_US
dc.subjectCSFen_US
dc.subjectCTCsen_US
dc.subjectctDNAen_US
dc.subjectliquid biopsyen_US
dc.subjectplasmaen_US
dc.titleLiquid biopsy in CNS tumors: Current status & future perspectivesen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJPM2022v65s1p111.pdf
Size:
1.06 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Pathology & Microbiology